Trial Profile
A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 19 May 2017
Price :
$35
*
At a glance
- Drugs Atenolol (Primary) ; Droxidopa (Primary)
- Indications Chronic fatigue syndrome; Postural orthostatic tachycardia syndrome
- Focus Therapeutic Use
- 08 Mar 2017 New trial record